Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.

Jahanzeb, Mohammad; E Mortimer, Joanne; Yunus, Furhan; H Irwin, David; Speyer, James; J Koletsky, Alan; Klein, Paula; Sabir, Tariq; Kronish, Lori

doi:10.1634/theoncologist.7-5-410

Public

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.

Published in The oncologist • Jan 1, 2002

Authors:

Mohammad Jahanzeb

Joanne E Mortimer

Furhan Yunus

Abstract

PURPOSE: Human epidermal growth factor receptor 2 (HER2) overexpression is associated with a more aggressive form of breast cancer that responds well to trastuzumab therapy. Trastuzumab-based combination regimens have shown greater antitumor activity than chemotherapy alone. These findings, coupled ...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!